610 / 1082
S594
ESTRO 36 2017
_______________________________________________________________________________________________
showed no correlation between EGFR and nomogram score
(ρ=0.29). After validating the existing nomogram with this
new cohort, its performance was comparable to the
published data
1
(C-index = 0.68). By performing
multivariate Cox regression, the addition of EGFR to the
nomogram improved its concordance index to 0.73 as
shown in table 1. Interestingly we found that high-risk
patients had lower EGFR levels in blood samples compared
to low-risk patients. This is opposite to results obtained
from tissue samples as reported in literature.
2
Conclusion
EGFR as blood biomarker is an independent predictor for
OS of patients with laryngeal carcinoma. OS curves for
patients in high vs low EGFR group are visible in figure 1.
Based on this small cohort the prognostic value of our
existing nomogram was improved, but an independent
cohort would be needed for external validation. Further
research is needed to correlate EGFR blood values
with EGFR expression in tumor samples.
References:
1. Egelmeer AGTM et al. Development and validation of a
nomogram for prediction of survival and local control in
laryngeal carcinoma patients treated with radiotherapy
alone: A cohort study based on 994 patients.
Radiother
Oncol
. 2011;100(1):108.
2. Ang KK et al. Impact of Epidermal Growth Factor
Receptor Expression on Survival and Pattern of Relapse in
Patients with Advanced Head and Neck Carcinoma.
Canc
Res.
2002;(713):7350.
EP-1089 Prospective study of body composition
changes during IMRT for H&N cancer as assessed
by DXA scans
J. Johansen
1
, A. Hermann
2
, S. Lønbro
3
1
Odense University Hospital, Oncology, Odense, Denmark
2
Odense University Hospital, Dept. of Endocrinology,
Odense, Denmark
3
Aarhus University, Dept. of Public Health- Section for
Sport Science, Aarhus, Denmark
Purpose or Objective
Weight loss is common after radiation treatment of head
and neck cancer (H&N) as assessed by only pre/post
measurements. Thus, only scarce data exists regarding
body changes during overall treatment time. This study
investigated changes in weight and body composition of
H&N patients during radical radiation treatment, and
correlated the findings to individual tests of muscle
strength.
Material and Methods
Prospective study of 30 H&N patients undergoing IMRT (60-
68 Gy) during a 16 month period. Patients were followed
weekly during treatment, and all had individualized
nutritional counseling. At baseline, and with 2-week
intervals during IMRT and 2 weeks after, patients
underwent whole-body dual-energy X-ray absoptiometry
(DXA) scans, as well as weight measurements and pre/post
treatment maximal muscle strength tests (n=21)(one-
repetition maximum chest press, leg press, and knee
extension). Changes over time were analyzed by linear
regression, and pre/post data were compared by Student’s
paired t-tests.
Results
A total of 131 DXA scans were obtained. Mean age was
58.2, and the patients were predominantly stage II-IV
(77%). Two-thirds received concomitant chemotherapy.
Baseline BMI was 27.4 (± 4.8). Significant overall declines
(p<0.001) were observed in weight (-8.2%; range +2.0 to -
18.4), fat mass (10.3%; range +2.4 to -29.1), and lean body
mass (10.7%; range +0.8 to -23.9). All changes were
mutually correlated in regression analysis, e.g., R
2
=0.74
(p<0.001) for weight loss versus lean body mass. The
decline in lean body mass was correlated with loss of
muscle strength as assessed by chest press (R
2
=0.61;
p<0.001) and knee extension (R
2
=0.25; p=0.03), but not
with leg press (p=.08). Concomitant chemoradiation was
associated with a 10% decline in lean body mass in
univariate analysis, however, no independent predictors
were discerned in multivariate regression.
Conclusion
The overall weight loss during IMRT for H&N was 8.2%.
Weight loss correlated proportionally with the percentage
decline in both fat mass and lean body mass. Loss of lean
body mass correlated well with loss of muscle strength
during treatment. The proportional loss of fat and lean
body mass indicates that physical exercise during
radiotherapy may be required to favor muscle/fat
distribution.
EP-1090 Particle therapy and IMRT for patients with
esthesioneuroblastoma: a single-institution experience
J. Liermann
1
, M. Syed
1
, D. Bernhardt
1
, N. Bougatf
2
, S.B.
Harrabi
1
, A. Paul
1
, T. Sprave
1
, S. Rieken
1
, T. Haberer
2
, K.
Herfarth
1
, J. Debus
1
, H. Hauswald
1
, S. Adeberg
1
1
University Hospital of Heidelberg, Department of
Radiation Oncology, Heidelberg, Germany
2
University Hospital of Heidelberg, Heidelberg Ion-Beam
Therapy Center HIT, Heidelberg, Germany
Purpose or Objective
Esthesioneuroblastoma or olfactory neuroblastoma is a
rare tumor entity originating from the olfactory
neuroepithelium. There is only few data about the
efficacy of different treatment strategies so far. Several
approaches have been made and a combination of
radiation and surgery is thought to be effective. Most
tumors are situated in the nasal cavity and thus applied
radiation therapy (RT) should be very precise. Intensity
modulated radiotherapy (IMRT) and carbon ion
radiotherapy (CIRT) are highly precise techniques with
advanced dose conformity and improved sparing of organs
at risk which might translate into improved local control
and moderate radiation induced toxicity.
Material and Methods
The retrospective analysis contained 17 patients with
esthesioneuroblastoma (Kadish stage ≥ C: 88%; n=15). 4